Suppr超能文献

比较眼内容剜除术与质子束放疗治疗大型脉络膜黑色素瘤患者的临床疗效。

Comparison of clinical outcomes for patients with large choroidal melanoma after primary treatment with enucleation or proton beam radiotherapy.

机构信息

Ocular Oncology Center, Galliera Hospital, Genoa, Italy.

出版信息

Ophthalmologica. 2012;227(4):190-6. doi: 10.1159/000334401. Epub 2012 Jan 20.

Abstract

PURPOSE

To evaluate survival and clinical outcome for patients with a large uveal melanoma treated by either enucleation or proton beam radiotherapy (PBRT).

PROCEDURES

This retrospective non-randomized study evaluated 132 consecutive patients with T3 and T4 choroidal melanoma classified according to TNM stage grouping.

RESULTS

Cumulative all-cause mortality, melanoma-related mortality and metastasis-free survival were not statistically different between the two groups (log-rank test, p = 0.56, p = 0.99 and p = 0.25, respectively). Eye retention of the tumours treated with PBRT at 5 years was 74% (SD 6.2%). In these patients at diagnosis, 73% of eyes had a best-corrected visual acuity (BCVA) of 0.1 or better. After 12 and 60 months, BCVA of 0.1 or better was observed in 47.5 and 32%, respectively.

CONCLUSION AND MESSAGE

Although enucleation is the most common primary treatment for large uveal melanomas, PBRT is an eye-preserving option that may be considered for some patients.

摘要

目的

评估接受眼球摘除术或质子束放射疗法(PBRT)治疗的大型脉络膜黑色素瘤患者的生存和临床结局。

方法

本回顾性非随机研究评估了根据 TNM 分期分组的 132 例连续 T3 和 T4 脉络膜黑色素瘤患者。

结果

两组患者的全因死亡率、黑色素瘤相关死亡率和无转移生存率无统计学差异(对数秩检验,p = 0.56、p = 0.99 和 p = 0.25)。接受 PBRT 治疗的肿瘤 5 年眼球保留率为 74%(SD 6.2%)。在这些患者诊断时,73%的眼睛最佳矫正视力(BCVA)为 0.1 或更好。在 12 个月和 60 个月时,BCVA 为 0.1 或更好的分别为 47.5%和 32%。

结论

尽管眼球摘除术是大型脉络膜黑色素瘤最常见的主要治疗方法,但 PBRT 是一种保留眼球的选择,可考虑用于某些患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验